Network Pharmacology and Experimental Validation to Reveal Effects and Mechanisms of Icariin Combined with Nobiletin against Chronic Obstructive Pulmonary Diseases

Ruilong Lu, Kexin Xu, Yanqin Qin, Xuejie Shao, Miaomiao Yan, Yixi Liao, Bo Wang, Jie Zhao, Jiansheng Li, Yange TianEvidence-based 2022 · DOI

TL;DR

This study investigates the therapeutic mechanisms of icariin and nobiletin (I&N) for Chronic Obstructive Pulmonary Disease (COPD) using a combination of network pharmacology and experimental validation. The findings suggest that I&N effectively treats COPD by inhibiting inflammation, primarily through the MAPK and PI3K-Akt signaling pathways.

What Problem Does This Paper Address?

Chronic Obstructive Pulmonary Disease (COPD) is a major global health issue characterized by persistent airflow limitation and inflammation. While traditional Chinese medicine (TCM) has shown promise in treating COPD, the precise molecular mechanisms and therapeutic targets are often unclear. Icariin and nobiletin, active compounds from a TCM formula, have demonstrated beneficial effects, but a comprehensive understanding of how they work against COPD is lacking. This paper aims to bridge this knowledge gap by identifying the key molecular targets and pathways involved in I&N's therapeutic action against COPD.

Methods

The study employed a two-pronged approach:

  • Network Pharmacology: This computational method was used to predict the potential targets and mechanisms of I&N.
  • Target Identification: Molecular targets of icariin and nobiletin were identified using databases like SwissTargetPrediction, STITCH, and PharmMapper. COPD-related genes were gathered from GeneCards, DrugBank, and DisGeNet.
  • Network Construction: A component-target (C-T) network was built to visualize the relationships between I&N components and COPD targets.
  • Protein-Protein Interaction (PPI) Network Analysis: A PPI network was constructed using STRING to identify key therapeutic targets based on topological characteristics (degree, betweenness centrality, closeness centrality).
  • Enrichment Analysis: Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed on the identified key targets to understand the biological processes and signaling pathways involved.
  • Molecular Docking: This technique was used to predict the binding affinity and mode between I&N and selected key protein targets, providing experimental evidence for potential interactions.
  • Experimental Validation: In vivo experiments were conducted to confirm the predicted therapeutic effects and mechanisms.
  • COPD Rat Model: A COPD rat model was established by exposing rats to cigarette smoke (CSE) and Klebsiella pneumoniae infection.
  • Treatment Groups: Rats were divided into control, COPD model, I&N treatment, and doxofylline (a known COPD treatment) control groups.
  • Outcome Measures: * Lung Function: Assessed using tidal volume (TV), peak expiratory flow (PEF), and 50% tidal volume expiratory flow (EF50).
  • Lung Tissue Histopathology: Evaluated for alveolar damage and airway wall thickness using hematoxylin and eosin (H&E) staining.
  • Inflammatory Response: Measured by quantifying mRNA and protein levels of inflammatory cytokines (IL-6, IL-1β, TNF-α) using ELISA and qPCR.
  • Signaling Pathway Verification: Western blotting was used to assess the expression and phosphorylation levels of key proteins in the PI3K-Akt and MAPK pathways (PI3K, P-AKT, P-p38).

Datasets

The study utilized publicly available databases for network pharmacology analysis:

  • Compound Targets: SwissTargetPrediction, STITCH 5.0, PharmMapper, PubChem.
  • COPD Genes: GeneCards, DrugBank, DisGeNet.
  • Protein-Protein Interactions: STRING database.
  • Gene Ontology and KEGG Pathways: DAVID 6.8.
  • Protein Structures: RCSB Protein Data Bank.

No new datasets were introduced in this study.

Key Insights and Ideas

  • Network Pharmacology as a Powerful Tool for TCM: The study effectively demonstrates how network pharmacology can unravel the complex, multi-target mechanisms of traditional Chinese medicine compounds like icariin and nobiletin.
  • Inflammation as a Central Target: The findings strongly implicate inflammation as the primary mechanism through which I&N exerts its therapeutic effects on COPD.
  • Key Pathways Identified: The research pinpoints the Tumor Necrosis Factor (TNF), Mitogen-Activated Protein Kinase (MAPK), and Phosphatidylinositol 3-kinase (PI3K)-Protein Kinase B (AKT) pathways as crucial mediators of I&N's action.
  • Synergistic Action of Icariin and Nobiletin: The combined use of icariin and nobiletin appears to offer a more comprehensive therapeutic effect than either compound alone, as suggested by the network analysis and experimental validation.
  • Experimental Validation Reinforces Computational Predictions: The in vivo experiments successfully validated the computational predictions, showing that I&N improves lung function, reduces inflammation, and modulates the identified signaling pathways.

Key Results

  • Target Identification: 445 potential targets for I&N and 1831 related genes for COPD were identified. A total of 189 overlapping genes were selected for further analysis.
  • Key Targets: 16 key targets were identified through PPI network analysis, including TNF, AKT1, VEGFA, EGFR, JUN, SRC, and MMP9.
  • Pathway Enrichment: GO and KEGG analyses revealed enrichment in inflammation-related pathways, particularly TNF, PI3K-Akt, and MAPK signaling.
  • Molecular Docking: Icariin and nobiletin showed strong binding affinities with key targets like AKT, TNF, EGFR, and MMP9.
  • In Vivo Efficacy:
    • I&N significantly improved lung function (TV, PEF, EF50) in COPD rats.
  • Histopathological analysis showed reduced alveolar damage and airway wall thickness.
  • I&N treatment significantly decreased the levels of inflammatory cytokines (IL-6, IL-1β, TNF-α) in lung tissues.
  • I&N inhibited the phosphorylation of PI3K, AKT, and p38, indicating modulation of the PI3K-Akt and MAPK pathways.
  • Comparison with Doxofylline: The therapeutic effects of I&N were comparable to those of doxofylline, a standard COPD treatment, in improving lung function and reducing inflammation.

Limitations and Future Work

  • Complexity of TCM Mechanisms: The authors acknowledge that the complex mechanisms of I&N for COPD treatment require further exploration.
  • Further Target Identification: While 16 key targets were identified, the study suggests that a deeper investigation into the roles of these and other potential targets is warranted.
  • In Vitro Studies: While in vivo experiments were conducted, further in vitro studies could provide more detailed mechanistic insights into the cellular and molecular interactions.
  • Long-Term Effects: The study focused on a specific treatment duration; investigating the long-term effects of I&N would be beneficial.
  • Clinical Translation: While promising, further research is needed to translate these findings into clinical applications for COPD patients.

Summary updated

Abstract

Icariin combined with nobiletin has therapeutic effects on COPD by inhibiting inflammation. The potential mechanisms of I&N may relate to the MAPK pathway and PI3K-Akt pathway.
BibTeX
@inproceedings{lu2022network,
  author = {Ruilong Lu and Kexin Xu and Yanqin Qin and Xuejie Shao and Miaomiao Yan and Yixi Liao and Bo Wang and Jie Zhao and Jiansheng Li and Yange Tian},
  title = {{Network Pharmacology and Experimental Validation to Reveal Effects and Mechanisms of Icariin Combined with Nobiletin against Chronic Obstructive Pulmonary Diseases}},
  booktitle = {Evidence-based},
  year = {2022},
  doi = {10.1155/2022/4838650},
}
Figure